Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib and Pembrolizumab in Surgically Resectable Oral Cavity Squamous Cell Carcinoma
NCT07484139Phase 2Not yet recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in oral cavity squamous cell carcinoma (OCSCC), sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT07484139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484139.